UCT-000445 / 1200 Pharma - LARVOL DELTA

The discovery and preclinical characterization of the SAM-competitive PRMT5 inhibitor UCT-000445 (AACR 2023) - "UCT-000445 was well tolerated in vivo and using a CD-1 nude mouse model we found that while reticulocyte proliferation (a surrogate marker for bone marrow cytopenias) is abrogated by continuous treatment with UCT-000445, the use of intermittent dosing schedules overcomes this effect, while yielding equivalent efficacy. Our data with UCT-000445 indicate that SAM-competitive PRMT5 inhibitors may represent a novel and compelling therapeutic strategy for the treatment of multiple solid tumors."

Preclinical • Colon Cancer • Hematological Malignancies • Lung Cancer • Oncology • Solid Tumor • FBXO11 • MTAP • PRMT5